CervoMed Inc. Common Stock
CRVOCervoMed Inc. (CRVO) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative and inflammatory diseases. The company leverages advanced scientific research to create novel treatment options aimed at improving patient outcomes in areas with significant unmet medical needs.
Company News
CervoMed will present new data on neflamapimod, a potential treatment for Dementia with Lewy Bodies (DLB), at the 18th Clinical Trials on Alzheimer's Disease Conference, highlighting results from their Phase 2b RewinD-LB trial.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Canaccord Genuity boosted the price target for CervoMed Inc. (NASDAQ: CRVO) from $50 to $65. Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rati...
